Atlas Trials

Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD

Clinical trial NCT03170895 · COMPLETED

Trial details

NCT number
NCT03170895
Sponsor
The University of Hong Kong
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
AMLFLT3-ITD Mutation
Start date
2017-07-01
Primary completion
2020-02-01
Enrollment
5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.